Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

Phase 1

Recruiting

Conditions: Small Cell Lung Carcinoma (SCLC)

Interventions: Drug: BI 764532
Drug: Etoposide
Drug: Carboplatin
Drug: Cisplatin
Drug: Durvalumab
Drug: Atezolizumab

First Posted Date: 2023-10-11

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT06077500

Locations: 🇪🇸
Hospital Virgen Macarena, Sevilla, Spain
🇧🇪
Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium
🇫🇷
INS Bergonie, Bordeaux, France

and more 11 locations

A Study in Healthy Men to Test How BI 1810631 is Taken up in the Body When Taken With or Without Food

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1810631

First Posted Date: 2023-10-10

Last Posted Date: 2024-10-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT06075277

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

A Study in Healthy People to Test Whether Iclepertin Has an Effect on Cardiac Safety

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Iclepertin
Drug: Iclepertin Placebo
Drug: Moxifloxacin Placebo
Drug: Moxifloxacin

First Posted Date: 2023-10-06

Last Posted Date: 2024-07-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 56

Registration Number: NCT06070597

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

A Study in Healthy Men to Test Whether BI 1015550 Influences the Amount of Nintedanib and Pirfenidone in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1015550
Drug: Nintedanib
Drug: Pirfenidone

First Posted Date: 2023-10-06

Last Posted Date: 2023-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT06070610

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity
Diabetes Mellitus, Type 2

Interventions: Drug: Survodutide
Drug: Placebo

First Posted Date: 2023-10-04

Last Posted Date: 2024-12-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 755

Registration Number: NCT06066528

Locations: 🇺🇸
EmVenio Research-Atlanta-69582, Phoenix, Arizona, United States
🇺🇸
Alliance for Multispecialty Research-Coral Gables-68872, Coral Gables, Florida, United States
🇺🇸
East Coast Institute for Research, LLC-Jacksonville-55146, Jacksonville, Florida, United States

and more 140 locations

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

Phase 3

Active, not recruiting

Conditions: Obesity

Interventions: Drug: survodutide
Drug: Placebo

First Posted Date: 2023-10-04

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 727

Registration Number: NCT06066515

Locations: 🇨🇳
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
🇨🇳
Huzhou Central Hospital, Huzhou, China
🇨🇳
Center Hospital of Jinan, Jinan, China

and more 114 locations

Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

Phase 3

Active, not recruiting

Conditions: Liposarcoma, Dedifferentiated

Interventions: Drug: Brigimadlin

First Posted Date: 2023-09-28

Last Posted Date: 2024-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 240

Registration Number: NCT06058793

Locations: 🇯🇵
National Cancer Center Hospital, Tokyo, Chuo-ku, Japan
🇺🇸
Precision NextGen Oncology, Beverly Hills, California, United States
🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States

and more 58 locations

A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Phase 1

Recruiting

Conditions: Solid Tumor, KRAS Mutation

Interventions: Drug: BI 3706674

First Posted Date: 2023-09-28

Last Posted Date: 2024-11-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 146

Registration Number: NCT06056024

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Korea, Republic of

and more 14 locations

Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol Change

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2023-09-25

Last Posted Date: 2024-10-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 3015000

Registration Number: NCT06053541

Locations: 🇧🇷
Boehringer Ingelheim Brasil, São Paulo, Brazil

A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1584862
Drug: itraconazole

First Posted Date: 2023-09-18

Last Posted Date: 2023-11-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT06041438

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy